特应性皮炎仍然是影响全球各种人群的普遍问题。虽然已经采用了许多治疗选择，吡美莫司仍然是一个有效和可行的选择。最近,人们对吡美莫司及其载体的安全性和有效性的比较越来越感兴趣。
■作者对几个数据库进行了全面搜索，包括PubMed,Cochrane,MEDLINE,和CochraneCentral,从成立到2022年5月，使用带有布尔运算符的广泛搜索策略。作者还采用了向后滚雪球来识别最初搜索中遗漏的任何研究。作者在我们的荟萃分析中纳入了随机对照试验，并从确定的研究中提取了数据。作者使用ReviewManager(RevMan)5.4版来分析数据，由于观察到研究人群和设置的差异，选择随机效应模型。作者认为P值为0.05或更低具有统计学意义。
■作者最初确定了211项研究，其中13项随机对照试验纳入4180名参与者进行分析.我们的汇总分析显示，吡美莫司1％比其载体更有效地降低特应性皮炎的严重程度。然而,吡美莫司和溶媒之间的不良反应没有显着差异，除了发热,鼻咽炎,头痛,与吡美莫司一起增加。
■我们的荟萃分析表明，吡美莫司1％比载体更有效，尽管安全状况仍然没有定论。吡美莫司降低了研究者的全球评估得分，湿疹面积和严重程度指数评分，以及与其车辆相比瘙痒的严重程度，表明更高的疗效。这是评估1％吡美莫司对载体的疗效和安全性的首批荟萃分析之一，并可能有助于医生做出明智的决定。
Atopic dermatitis remains a widespread problem affecting various populations globally. While numerous treatment options have been employed, pimecrolimus remains a potent and viable option. Recently, there has been increasing interest in comparing the safety and efficacy of pimecrolimus with its vehicle.
UNASSIGNED: The authors conducted a comprehensive search of several databases, including PubMed, COCHRANE, MEDLINE, and Cochrane Central, from inception to May 2022, using a wide search strategy with Boolean operators. The authors also employed backward snowballing to identify any studies missed in the initial search. The authors included randomized controlled trials in our meta-analysis and extracted data from the identified studies. The authors used Review Manager (RevMan) Version 5.4 to analyze the data, selecting a random-effects model due to observed differences in study populations and settings. The authors considered a P-value of 0.05 or lower to be statistically significant.
UNASSIGNED: The authors initially identified 211 studies, of which 13 randomized controlled trials involving 4180 participants were selected for analysis. Our pooled analysis revealed that pimecrolimus 1% was more effective at reducing the severity of atopic dermatitis than its vehicles. However, no significant difference was observed in adverse effects between pimecrolimus and vehicle, except for pyrexia, nasopharyngitis, and headache, which were increased with pimecrolimus.
UNASSIGNED: Our meta-analysis showed that pimecrolimus 1% is more effective than vehicle, although the safety profile remains inconclusive. Pimecrolimus reduced the Investigator\'s Global Assessment score, Eczema Area and Severity Index score, and severity of pruritus when compared to its vehicle, indicating a higher efficacy profile. This is one of the first meta-analyses to assess the efficacy and safety profile of pimecrolimus 1% against a vehicle and may assist physicians in making informed decisions.
PDF(Pubmed)